Comparing the current results to its competitors, Beam Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -94.21 %, despite the revenue increase by the most of its competitors of 20 %, recorded in the same quarter.
November 5, 2024
Advancements in Hematology: Beam Therapeutics Innovative Research Amidst Financial Challenges Beam Therapeutics, a leading biotechnology company focused on developing precision genetic medicines through base editing, recently made significant presentations at the American Society of Hematology (ASH) Annual Meeting. The data presented encapsulates crucial insights from their hematology franchise, particularly highlighting the first clinical data from the BEAM-101 trial in sickle cell disease. Despite the promising clinical advances, Beam Therapeutics experienced notable economic hurdles in the second quarter of 2024. Clinical Advances in Sickle Cell DiseaseAt the ASH Annual Meeting, Beam Therapeutics presen...
March 26, 2024
Beam Therapeutics Announces Clearance of Clinical Trial Authorization Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)Beam Therapeutics, a leading biotechnology company, has recently announced the clearance of its clinical trial authorization application for BEAM-302, a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD). This milestone brings new hope for patients suffering from this rare genetic disorder. AATD is characterized by a deficiency of the Alpha-1 Antitrypsin protein, leading to lung and liver diseases.The clearance of the clinical trial authorization application signifies an essential step towards conducting human trials to evaluate the safety and eff...
Jasper Therapeutics Inc operates in the biotechnology industry, focusing on developing stem cell-based therapies for hematopoietic and immune system disorders. Their business model involves utilizing innovative stem cell technologies and partnerships within the medical community to advance their research and bring potential treatments to patients in need.
Kodiak Sciences Inc operates as a biopharmaceutical company that focuses on researching, developing, and commercializing innovative therapeutics to treat various retinal diseases. Their business model revolves around the discovery and development of novel drugs, while also conducting clinical trials and pursuing partnerships to bring these therapies to the market.
LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
Sources:
Beam Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Beam Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
